Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma
Panelists discuss how determining a patient's readiness to transition back to community oncology care after bispecific therapy involves assessing multiple factors including treatment response, toxicity resolution, overall stability, and the community practice's capabilities.
Video content above is prompted by the following:
- What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after bispecific therapy? (e.g. time since treatment, resolution of toxicities, evidence of response)
- How do social factors play into the referral process?
- How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
- How are they managed?
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
